Posts

Showing posts from October, 2024

Cimetidine (H2 Antihistamines)

Image
  [First gen histamine H2 receptor antagonist that inhibits stomach acid production. Has direct anti-proliferative effects on cancer cells, inhibits cell adhesion, reduces tumour angiogenesis (growth of blood vessels essential to a developing tumour) and also boosts anti-cancer immunity in various cancers.] ( link ) Cimetidine Life Extension report (excellent!): https://www.lifeextension.com/magazine/2007/5/report_cimetidine Cimetidine Anti Cancer Drug Reverses Tumor Immunity https://jeffreydachmd.com/cimetidine-anti-cancer-drug-reverses-tumor-immunity/ High-dose cimetidine for the treatment of metastatic renal cell carcinoma. A Hoosier Oncology Group study. The Hoosier Oncology Group evaluated cimetidine in 42 patients with metastatic renal cell carcinoma. There were two complete remissions that lasted for 26 and 33+ months in 38 evaluable patients. There were no partial remissions. Toxicity was minimal. Patients with renal cell carcinoma can occasionally respond to cimetidine wit...

Bisphosphonates

Image
  Osteoporosis and Fracture Prevention: Bisphosphonates are the most widely used medications for osteoporosis. Alendronate, risedronate, ibandronate, and zoledronic acid are the most common. Alendronate reduces vertebral fractures by 50% and non-vertebral fractures by 50% in women with prevalent vertebral fractures. It reduces hip fracture risk by 34% in the oldest old patients (Black et al., 1996; Cummings et al., 1998; Axelsson et al., 2017). Yearly IV zoledronic acid reduces vertebral fractures by 70% and hip fractures by 40% in postmenopausal women. It also reduces fracture risk when given after a hip fracture (Black et al., 2007; Lyles et al., 2007). A 2017 meta-analysis found bisphosphonates significantly reduced overall osteoporotic fracture risk (OR 0.62), vertebral fractures (OR 0.55), and non-vertebral fractures (OR 0.73) compared to placebo. Zoledronic acid showed the greatest reduction in overall fracture risk (OR 0.61) (Tan et al., 2017). Muscle Mass and Strength: Some...